New study aims to predict cancer return in Low-Risk patients
NCT ID NCT04604613
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifying who is most at risk of recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIGO GRADE 1 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a hormonal IUD replace surgery for some uterine cancers?
- Weight-loss shot plus IUD may help reverse womb cancer without surgery
- Remote strength training aims to boost endometrial cancer survivorship in rural areas
- New drug combo aims to outsmart Chemo-Resistant ovarian cancer
- New combo therapy shows promise for Tough-to-Treat endometrial cancer
- Do tiny cancer cells in lymph nodes matter? new study aims to find out